HSIC Stock Cash Flow Statements

Henry Schein Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Henry Schein Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2021-12-25	2021-09-25	2020-06-27	2020-03-28	2019-12-28	2019-09-28	2019-06-29	2019-03-30	2018-03-31	2017-09-30	2017-07-01	2017-04-01	2010-03-27	2009-12-26	2009-09-26	2009-06-27	2009-03-28	2008-09-27	2008-06-28	2008-03-29	2007-12-29	2007-09-29	2007-06-30	2007-03-31	2006-12-30	2006-09-30	2006-07-01	2006-04-01	2005-12-31	2005-09-24	2005-06-25	2005-03-26	2004-12-25	2004-09-25	2004-06-26	2004-03-27

cash flows from operating activities:
net income	152,147,000	169,474,000	-13,267,000	133,565,000	336,445,000	148,853,000							67,252,000	92,684,000	100,745,000			68,425,000	65,477,000	52,330,000	78,269,000	59,573,000	33,837,000	43,494,000	62,997,000	39,285,000	45,218,000	16,259,000	51,700,000	26,427,000	39,974,000	33,225,000	29,550,000	31,504,000	38,736,000	28,393,000
income from discontinued operations			585,000	-282,000	-747,000	5,641,000
income from continuing operations	152,147,000	169,474,000	-13,852,000	133,847,000	337,192,000	143,212,000
adjustments to reconcile net income to net cash from operating activities:
net cash from operating activities from continuing operations	276,639,000	211,215,000	-91,600,000	90,757,000	295,298,000	226,394,000
net cash from operating activities from discontinued operations			855,000	-282,000	-2,738,000	5,641,000
net cash from operating activities	276,639,000	211,215,000	-90,745,000	90,475,000	292,560,000	232,035,000							21,675,000	178,513,000	138,802,000	106,703,000	-27,128,000	49,947,000	125,277,000	13,340,000	120,286,000	69,184,000	114,643,000	-33,902,000	170,691,000	64,009,000	38,617,000	-38,000,000	151,559,000	40,967,000	87,910,000	-15,295,000			81,045,000	-20,302,000
cash flows from investing activities:
purchases of fixed assets	-30,309,000	-16,894,000	-7,580,000	-23,008,000	-27,263,000	-18,248,000							-9,062,000	-13,210,000	-10,014,000	-15,537,000	-12,866,000	-14,653,000	-9,723,000	-13,743,000	-23,798,000	-11,687,000	-12,403,000	-8,933,000	-17,073,000	-17,273,000	-21,486,000	-11,168,000	-14,625,000	-14,171,000	-13,895,000	-8,138,000	-13,150,000
payments related to equity investments and business
proceeds from sale of equity investment					296,751,000	0
proceeds from (repayments to) loan to affiliate
other	-14,604,000	-7,073,000	-5,812,000	-5,787,000	-1,927,000	-3,486,000							1,361,000	-162,000	1,044,000	-125,000	1,616,000	-815,000	-891,000	-426,000	-3,642,000	-2,300,000	151,000	-721,000	483,000	-2,137,000	701,000	-1,113,000	-1,299,000	1,058,000	-1,079,000	1,089,000	-2,514,000	3,945,000	-56,000	144,000
net cash from investing activities from continuing operations	-198,216,000	-137,882,000	-16,036,000	-65,605,000	269,040,000	-55,806,000
net cash from investing activities from discontinued operations					0	0
net cash from investing activities	-198,216,000	-137,882,000	-16,036,000	-65,605,000	269,040,000	-55,806,000							-144,412,000	28,417,000	-72,608,000	-25,377,000	-27,880,000	-2,999,000	-22,522,000	-60,084,000	-82,019,000	-40,646,000	-74,334,000	-45,048,000	-81,340,000	-5,968,000	-8,223,000	-84,830,000	-95,671,000	-4,038,000	-9,193,000	-53,964,000	5,564,000	18,866,000	-109,111,000	-87,871,000
cash flows from financing activities:
net change in bank borrowings	-5,280,000	-7,747,000	121,063,000	358,639,000
proceeds from issuance of long-term debt	105,000,000	0	251,421,000	250,000,000																	0	0	55,000	428,000									0
principal payments for long-term debt	-435,000	-1,509,000	-601,102,000	-8,478,000	-250,692,000	-1,214,000							-1,843,000	-877,000	-150,840,000	-900,000	-1,712,000	-24,190,000	-4,976,000	-973,000	-5,374,000	-24,604,000	-17,468,000	-457,000	-3,860,000	-24,202,000	-3,830,000	-2,645,000	-3,005,000	-2,913,000
debt issuance costs	-880,000	-1,814,000	-3,597,000	-58,000	0	0
debt extinguishment costs
proceeds from issuance of stock upon exercise of stock options					0	0							15,280,000	2,181,000	5,761,000	3,551,000	377,000	12,346,000	5,523,000	7,172,000	2,740,000	9,099,000	12,929,000	10,691,000	2,722,000	7,300,000	8,492,000	17,108,000	4,222,000	6,225,000	8,109,000	10,944,000	2,172,000	1,375,000	5,195,000	12,683,000
payments for repurchases of common stock			0	-73,789,000	-200,000,000	-98,218,000												-23,298,000			0	0	0	-30,689,000	-14,563,000	-2,261,000			-25,159,000	-6,108,000	-4,699,000	-16,310,000	-11,547,000	-24,702,000	-34,910,000	-11,054,000
payments for taxes related to shares withheld for employee taxes	-99,000	-13,000	-558,000	-13,155,000	-63,000	-224,000
distribution received related to animal health spin-off					0	0
proceeds related to animal health share sale					0	0
proceeds from (distributions to) noncontrolling shareholders			198,000	-3,664,000
acquisitions of noncontrolling interests in subsidiaries	-9,948,000	-49,162,000	-9,000	-14,925,000	0	-88,000							-10,000,000
proceeds from (payments) to henry schein animal health business
net cash from financing activities from continuing operations	-78,484,000	-115,078,000	-229,558,000	491,608,000	-539,490,000	-184,147,000
net cash from financing activities from discontinued operations			-855,000	282,000	2,738,000	-5,641,000
net cash from financing activities	-78,484,000	-115,078,000	-230,413,000	491,890,000	-536,752,000	-189,788,000							5,640,000	-50,777,000	-143,756,000	3,292,000	-6,434,000	-28,913,000	-33,422,000	5,285,000	3,732,000	-16,625,000	-3,062,000	-15,165,000	-12,909,000	-15,888,000	-14,902,000	22,425,000	-24,397,000	-7,323,000	-866,000	-6,280,000	-11,411,000	-48,833,000	61,176,000	25,438,000
effect of exchange rate changes on cash and cash equivalents from continuing operations	-1,107,000	-6,350,000	15,936,000	-5,489,000
effect of exchange rate changes on cash and cash equivalents from discontinued operations
net change in cash and cash equivalents from continuing operations	-1,168,000	-48,095,000	-321,258,000	511,271,000	30,841,000	-9,668,000
net change in cash and cash equivalents from discontinued operations					0	0
cash and cash equivalents, beginning of period	0	0	0	106,097,000	0	0							471,154,000		0	0	369,570,000	0	0	247,590,000		0	0	248,647,000		0	-43,815,000	254,498,000		0	0	186,621,000		0	0	157,351,000
cash and cash equivalents, end of period	-1,168,000	-48,095,000	-321,258,000	617,368,000	30,841,000	-9,668,000							355,388,000		-76,266,000	85,717,000	308,156,000	16,932,000	68,396,000	203,036,000		16,487,000	36,515,000	154,456,000		37,736,000	-21,556,000	159,890,000		32,969,000	72,367,000	114,741,000		-33,366,000	33,251,000	73,086,000
revenues:
health care distribution
technology and value-added services
total excluding corporate tsa revenues
corporate tsa revenues
corporate tsa revenues represents sales of certain animal health products to covetrus under the transition services agreement
proceeds from sale of equity investments
payments for loan to affiliate		-3,959,000
payments for repurchases and retirement of common stock
distributions to noncontrolling shareholders		-4,833,000
proceeds from henry schein animal health business
dental
medical
proceeds from (payments to) henry schein animal health business
repayments from loan to affiliate				1,137,000
payments to henry schein animal health business				-2,962,000	-2,738,000	46,400,000
net sales				319,522,000	2,860,278,000	-86,531,000
cost of goods sold				260,097,000
gross profit				59,425,000	518,136,000	-16,544,000
selling, general and administrative				64,894,000
operating income				-5,469,000	109,775,000	-1,585,000
income tax expense				4,764,000	35,293,000
net income attributable to noncontrolling interests				366,000													4,449,000
net income from discontinued operations
attributable to henry schein, inc.				-8,630,000	74,456,000	132,000
repayments from (borrowings for) loan to affiliate
net (income) loss attributable to noncontrolling interests					-6,500,000	2,321,000
payments for equity investments and business
proceeds/(payments) for loan to affiliate						580,000
proceeds from (repayments of) bank borrowings						-134,834,000															5,766,000				-113,000
proceeds from issuance of debt						0
proceeds from (distributions to) noncontrolling stockholders						4,031,000
effect of exchange rate changes on cash and cash equivalents-continuing operations						3,891,000
effect of exchange rate changes on cash and cash equivalents-discontinued operations						0
income taxes
net income .......................................................................................................................................................................................								114,644,000	148,631,000
income from discontinued operations............................................................................................................................................								-8,996,000
income from continuing operations.......................................................................................................................................................								123,640,000
adjustments to reconcile net income to net cash provided by
net cash from operating activities from continuing operations..............................................................................................								133,334,000
net cash from operating activities from discontinued operations..............................................................................................................								-167,073,000
net cash from operating activities ......................................................................................................................................................								-33,739,000	-70,944,000			-52,591,000
purchases of fixed assets ....................................................................................................................................................................								-15,918,000	-18,251,000	-18,350,000	-19,654,000	-17,311,000
proceeds from sale of equity investment.................................................................................................................................................								10,500,000
proceeds/(payments) for loan to affiliate................................................................................................................................................								15,940,000
other ...............................................................................................................................................................................................								-3,076,000
net cash from investing activities from continuing operations..................................................................................................................								-596,527,000
net cash from investing activities from discontinued operations...............................................................................................................								-2,064,000
net cash from investing activities .......................................................................................................................................................								-598,591,000				-34,680,000
proceeds from (repayments of) bank borrowings .....................................................................................................................................								-652,117,000
proceeds from issuance of debt ............................................................................................................................................................								741,000	100,000,000
principal payments for long-term debt ...................................................................................................................................................								-7,376,000				-56,367,000
debt issuance costs.............................................................................................................................................................................
proceeds from issuance of stock upon exercise of stock options .................................................................................................................								34,000	3,022,000	240,000	749,000	3,952,000
payments for repurchases of common stock ..........................................................................................................................................								-150,000,000				-50,006,000
payments for taxes related to shares withheld for employee taxes...............................................................................................................								-9,671,000				-40,605,000
distribution received related to animal health spin-off.............................................................................................................................								1,120,000,000
proceeds related to animal health share sale..........................................................................................................................................								361,090,000
proceeds from (distributions to) noncontrolling stockholders ......................................................................................................................								52,205,000
acquisitions of noncontrolling interests in subsidiaries ..............................................................................................................................								-6,057,000				-4,089,000
payments to henry schein animal health business..................................................................................................................................								-224,773,000
net cash from financing activities from continuing operations...........................................................................................................								484,076,000
net cash from financing activities from discontinued operations........................................................................................................								148,053,000
net cash from financing activities................................................................................................................................................								632,129,000
effect of exchange rate changes on cash & cash equivalents-continuing operations.......................................................................................								10,347,000
effect of exchange rate changes on cash & cash equivalents-discontinued operations....................................................................................								-2,240,000
net change in cash and cash equivalents from continuing operations...........................................................................................................								31,230,000
net change in cash and cash equivalents from discontinued operations........................................................................................................								-23,324,000
cash and cash equivalents, beginning of period .......................................................................................................................................								56,885,000	174,658,000	0	0	62,381,000
cash and cash equivalents, end of period ...............................................................................................................................................								88,115,000	99,235,000	5,225,000	11,766,000	62,888,000
net sales ..............................................................................................................................................................................								946,988,000
gross profit ..........................................................................................................................................................................								176,462,000
operating income...........................................................................................................................................................								43,901,000
income taxes .......................................................................................................................................................................								11,622,000
income from discontinued operations................................................................................................................................								33,914,000
net (income) loss attributable to noncontrolling interests...............................................................................................................								-5,230,000
net income from discontinued operations attributable to henry schein, inc..............................................................................								28,684,000
adjustments to reconcile net income to net cash used in
other ..............................................................................................................................................................................................									-8,212,000	-1,822,000	677,000	-5,549,000
net cash from investing activities ......................................................................................................................................................									-35,166,000
proceeds from bank borrowings ............................................................................................................................................................									212,055,000
debt issuance costs ...........................................................................................................................................................................									-30,000
principal payments for long-term debt ....................................................................................................................................................									-10,032,000
payments for repurchases of common stock ............................................................................................................................................
payments for taxes related to shares withheld for employee taxes.................................................................................................................									-15,012,000
distributions to noncontrolling stockholders ..........................................................................................................................................									-811,000
acquisitions of noncontrolling interests in subsidiaries ............................................................................................................................									-261,433,000
net cash from financing activities ................................................................................................................................................									27,759,000
effect of exchange rate changes on cash and cash equivalents ....................................................................................................................									2,928,000
net change in cash and cash equivalents ................................................................................................................................................									-75,423,000	5,225,000	11,766,000	507,000
balance sheet
assets:
prepaid expenses and other .........................................................................................................................................
investments and other ...............................................................................................................................................
liabilities:
accrued expenses -taxes............................................................................................................................................
accrued expenses - other ...........................................................................................................................................
deferred income taxes ...............................................................................................................................................
other liabilities (long-term) ........................................................................................................................................
stockholders' equity:
retained earnings .....................................................................................................................................................
net income ......................................................................................................................................................................................												150,253,000
net cash from operating activities ...............................................................................................................................................										131,362,000
proceeds from issuance of long-term debt ..............................................................................................................................................
debt issuance costs ............................................................................................................................................................................
excess tax benefits related to stock-based compensation..........................................................................................................................
distributions to noncontrolling shareholders ...........................................................................................................................................												-3,264,000
net cash from financing activities ...................................................................................................................................										594,000
effect of exchange rate changes on cash and cash equivalents ..................................................................................................................												4,120,000
net sales:
health care distribution :
technology and value-added services ...........................................................................................................................................												105,965,000
*cs
consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and
generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other
services.
operating income:
health care distribution ..................................................................................................................................................................												162,707,000
technology and value-added services ...............................................................................................................................................										-1,767,000	2,442,000	31,261,000
proceeds from (repayments of) bank borrowings ......................................................................................................................................
proceeds from issuance of long-term debt ...............................................................................................................................................
distributions to noncontrolling shareholders ..........................................................................................................................................
technology and value-added services ............................................................................................................................................
health care distribution ...................................................................................................................................................................
proceeds from bank borrowings ...........................................................................................................................................................												234,037,000
net cash from financing activities ...............................................................................................................................................												83,658,000
operating activities:
depreciation and amortization													24,572,000	20,563,000	20,196,000	20,813,000	19,921,000	19,475,000	20,270,000	19,438,000	20,915,000	17,794,000	17,670,000	17,557,000	18,039,000	16,733,000	15,806,000	14,352,000	17,798,000	14,199,000	15,111,000	13,237,000	18,095,000	13,247,000	10,342,000	9,642,000
amortization of bond discount													1,548,000	1,517,000	1,509,000	1,500,000	1,464,000
stock-based compensation expense													6,142,000	7,580,000	6,041,000	6,236,000	6,067,000	6,844,000	6,956,000	9,260,000	5,833,000	5,995,000	6,608,000	4,117,000	5,531,000	4,559,000	5,517,000	3,857,000
benefit from losses on trade and other accounts receivable													994,000	1,993,000	1,042,000	526,000	1,186,000	1,107,000	1,467,000	1,137,000	322,000	830,000	1,000	231,000	529,000				889,000				2,031,000
benefit from deferred income taxes													272,000	3,419,000	-23,712,000	-436,000	-5,485,000	1,600,000	448,000	-3,339,000	9,326,000	1,958,000													2,831,000	565,000
undistributed earnings of affiliates													-1,531,000		-1,200,000	-1,212,000	-1,365,000			-1,510,000				-23,000	-254,000	-246,000	-227,000	-108,000	-313,000	-79,000	-248,000	-187,000	-368,000	-746,000	-300,000	-285,000
changes in operating assets and liabilities, net of acquisitions:
accounts receivable													-7,394,000	33,233,000	-27,231,000	-28,954,000	43,397,000	-59,999,000	-23,256,000	16,504,000	60,557,000	-65,765,000	-12,809,000	-3,947,000	-287,000	-6,395,000	-7,622,000	4,599,000	27,643,000	-36,579,000	-19,500,000	14,434,000	-2,023,000	-18,119,000	-8,118,000	-6,815,000
inventories													14,482,000	-9,008,000	-23,482,000	34,287,000	-21,039,000	-63,118,000	16,023,000	-21,087,000	15,995,000	-47,387,000	11,510,000	3,936,000	-5,991,000	-4,212,000	-19,274,000	-12,481,000	-27,641,000	12,862,000	12,653,000	8,610,000	-18,338,000	10,874,000	1,959,000	-23,109,000
other current assets													7,730,000	1,181,000	-3,276,000	-10,199,000	12,669,000	-14,449,000	8,452,000	2,503,000	-48,353,000	-14,310,000	-7,413,000	11,882,000	11,048,000	-770,000	5,003,000	3,143,000	-11,505,000	7,637,000	1,225,000	32,790,000	-18,522,000	-5,135,000	-8,600,000	18,338,000
accounts payable and accrued expenses													-93,753,000	26,979,000	84,207,000	3,839,000	-144,859,000	82,539,000	24,108,000	-64,720,000	-23,158,000	103,334,000	39,884,000	-106,488,000	70,994,000	19,381,000	-9,731,000	-92,527,000	90,463,000	-3,187,000	35,521,000	-121,356,000	115,635,000	-41,906,000	42,253,000	-48,109,000
payments for equity investment and business
acquisitions, net of cash acquired													-108,946,000	41,263,000	-71,422,000	-12,746,000	-13,743,000	-2,349,000	-15,057,000	-8,524,000
purchases of available-for-sale securities													-26,984,000					0	0	-35,925,000	0	-27,065,000	-70,501,000	-17,500,000	-57,999,000	-16,697,000	-86,465,000	-60,875,000	-103,520,000
proceeds from sales of available-for-sale securities													1,300,000	1,225,000	4,690,000	1,300,000	2,740,000	725,000	0	847,000	27,750,000	87,315,000	30,000,000	18,000,000	8,000,000	117,806,000	108,066,000	60,895,000
net proceeds from foreign exchange forward contract settlements
repayments of bank borrowings													-931,000		-436,000	-204,000	-3,189,000	722,000	-2,589,000	-3,919,000
excess tax benefits related to stock-based compensation													4,522,000	1,859,000	2,138,000	503,000	180,000	5,962,000	1,244,000	3,429,000	1,071,000	3,575,000	2,169,000	5,853,000				6,925,000
net change in cash and cash equivalents													-117,097,000	156,153,000	-77,562,000	84,618,000	-61,442,000	18,035,000	69,333,000	-41,459,000	41,999,000	11,913,000	37,247,000	-94,115,000	76,442,000	42,153,000	15,492,000	-100,405,000	31,491,000	29,606,000	77,851,000	-75,539,000	127,573,000	-33,131,000	33,110,000	-82,735,000
effect of exchange rate changes on cash and cash equivalents													1,331,000	-2,606,000	1,296,000	1,099,000	28,000	-1,103,000	-937,000	-3,095,000	-1,867,000	4,574,000	-732,000	-76,000	-3,865,000	-4,417,000	6,767,000	5,797,000	2,930,000	3,363,000	-5,484,000	3,659,000	-13,923,000	-235,000	141,000	-1,530,000
adjustments to reconcile net income to net cash provided
by operating activities:
gain on sale of discontinued operation, net of tax														0
impairment from write-down of long-lived assets of
discontinued operation
stock issued to 401(k) plan														0							0				0				0				0
undistributed (earnings) losses of affiliates																		-1,602,000
cash received from business divestiture																									0	0
net proceeds from (payments for) foreign exchange
forward contract settlements
cash and cash equivalents, beginning of year
cash and cash equivalents, end of year
cash received from business divestitures																					10,766,000
net proceeds from (payments for) foreign exchange forward contract settlements																-8,000	283,000								-5,633,000	-2,090,000			7,188,000	8,115,000
net income attributable to henry schein, inc.																	54,851,000
adjustments to reconcile net income attributable to henry schein, inc. to net cash
provided by operating activities:
adjustments to reconcile net income to net cash
loss on sales of discontinued operation, net of tax
impairment from write-down of long-lived assets of discontinued operations
minority interest in net income of subsidiaries																		5,278,000	7,131,000	3,250,000	6,438,000	4,247,000	3,842,000	2,915,000	3,643,000	1,181,000	1,706,000	1,560,000	2,215,000	1,249,000	2,476,000	51,000	-221,000	-72,000	1,254,000	525,000
net payments for foreign exchange forward contract settlements																			-3,048,000	-2,004,000		-5,367,000	-7,692,000	-3,921,000				-1,161,000				-4,478,000
payments for equity investment and business acquisitions, net of cash acquired																					-81,884,000	-82,475,000	-14,391,000	-27,432,000
proceeds from maturities of available-for-sale securities																									2,000,000	0
proceeds from settlement of note receivable																													2,616,000
payments for debt issuance costs																													0				-627,000
loss on sale of discontinued operation, net of tax																									0	0	0	19,363,000
impairment from write down of long-lived assets of discontinued operations																						0
undistributed earnings (losses) of affiliates																						182,000
deferred income taxes																								-6,855,000	3,959,000	-8,599,000	959,000	4,978,000	1,609,000	-3,456,000	1,619,000	3,020,000	10,095,000
net proceeds from (repayments of) bank borrowings																								-255,000
impairment of long-lived asset
payments for business acquisitions, net of cash acquired																									-13,748,000	-80,945,000	-32,475,000	-72,712,000	-9,665,000	-3,796,000	-15,706,000	-39,046,000	19,654,000	-16,222,000	-131,406,000	-4,401,000
payments related to pending business acquisitions																																	-3,950,000	42,952,000	29,590,000	-86,031,000
repayments of debt assumed in business acquisitions
impairment from write-down of long-lived asset
proceeds from excess tax benefits related to stock-based compensation																										3,362,000
benefit from (recovery of) losses on trade and other accounts receivable																											561,000	118,000			158,000	-208,000
net payments on bank borrowings
payments for establishing a new credit facility
net proceeds from bank borrowings																												1,223,000				183,000
impairment from write-down of long-lived assets																													0
net payments for bank borrowings																													-637,000
proceeds from sales of marketable securities																																	0	0	0	14,472,000
net proceeds from (payments for) bank borrowings
payments for establishing new credit facility
net proceeds from short-term bank borrowings
principal payments on long-term debt																																-696,000	-295,000	-1,354,000	-1,448,000	-262,000
cash flows from operating activities of continuing operations:
net income from continuing operations																																	29,550,000
adjustments to reconcile net income to net cash from operating activities of continuing operations:
net cash from operating activities of continuing operations																																	133,420,000
purchases of marketable securities
proceeds from maturities of marketable securities
other, including discontinued operation																																	3,010,000
net (payments on) proceeds from bank borrowings
repayment of debt assumed in business acquisitions																																	0
net proceeds from (payments on) bank borrowings																																				24,417,000
benefit from losses and allowances on trade receivables																																			744,000	409,000
changes in operating assets and liabilities, net of effect of acquisitions:
purchases of capital expenditures																																			-8,135,000	-5,654,000
proceeds from bank borrowings
net proceeds from (payments on) short-term bank borrowings
stock issued to esop trust
accounts payable and accruals
net (payments on) borrowing from banks

We provide you with 20 years of cash flow statements for Henry Schein stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Henry Schein stock. Explore the full financial landscape of Henry Schein stock with our expertly curated income statements.

The information provided in this report about Henry Schein stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.